Literature DB >> 26833554

Effect of esomeprazole on the oral absorption of dasatinib in a patient with Philadelphia-positive acute lymphoblastic leukemia.

Elise Pape1, Delphine Michel2, Julien Scala-Bertola1, Thomas Schiestel1, Alexandre Harlé3,4,5, Stéphane Bouchet6, Audrey Contet2, Cécile Pochon2, Nicolas Gambier3.   

Abstract

Entities:  

Year:  2016        PMID： 26833554      PMCID： PMC4876178          DOI： 10.1111/bcp.12895

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


× No keyword cloud information.
  10 in total

1.  Influence of H2-receptor antagonists and proton pump inhibitors on dasatinib pharmacokinetics in Japanese leukemia patients.

Authors:  Naoto Takahashi; Masatomo Miura; Takenori Niioka; Kenichi Sawada
Journal:  Cancer Chemother Pharmacol       Date:  2011-12-07       Impact factor: 3.333

2.  Effect of esomeprazole on the oral absorption of dasatinib in a patient with Philadelphia-positive acute lymphoblastic leukemia.

Authors:  Elise Pape; Delphine Michel; Julien Scala-Bertola; Thomas Schiestel; Alexandre Harlé; Stéphane Bouchet; Audrey Contet; Cécile Pochon; Nicolas Gambier
Journal:  Br J Clin Pharmacol       Date:  2016-03-04       Impact factor: 4.335

3.  Simultaneous determination of nine tyrosine kinase inhibitors by 96-well solid-phase extraction and ultra performance LC/MS-MS.

Authors:  Stéphane Bouchet; Emmanuelle Chauzit; Dominique Ducint; Nadège Castaing; Mireille Canal-Raffin; Nicholas Moore; Karine Titier; Mathieu Molimard
Journal:  Clin Chim Acta       Date:  2011-02-21       Impact factor: 3.786

4.  Esomeprazole 40 mg provides more effective intragastric acid control than lansoprazole 30 mg, omeprazole 20 mg, pantoprazole 40 mg and rabeprazole 20 mg in patients with gastro-oesophageal reflux symptoms.

Authors:  Kerstin Röhss; Tore Lind; Clive Wilder-Smith
Journal:  Eur J Clin Pharmacol       Date:  2004-09-02       Impact factor: 2.953

5.  Phase I study of the effect of gastric acid pH modulators on the bioavailability of oral dasatinib in healthy subjects.

Authors:  Timothy Eley; Feng R Luo; Shruti Agrawal; Ashish Sanil; James Manning; Tong Li; Anne Blackwood-Chirchir; Richard Bertz
Journal:  J Clin Pharmacol       Date:  2009-04-24       Impact factor: 3.126

6.  Metabolism and disposition of dasatinib after oral administration to humans.

Authors:  Lisa J Christopher; Donghui Cui; Chiyuan Wu; Roger Luo; James A Manning; Samuel J Bonacorsi; Michael Lago; Alban Allentoff; Francis Y F Lee; Betty McCann; Susan Galbraith; Donald P Reitberg; Kan He; Anthony Barros; Anne Blackwood-Chirchir; W Griffith Humphreys; Ramaswamy A Iyer
Journal:  Drug Metab Dispos       Date:  2008-04-17       Impact factor: 3.922

Review 7.  Relative potency of proton-pump inhibitors-comparison of effects on intragastric pH.

Authors:  Julia Kirchheiner; Silke Glatt; Uwe Fuhr; Ulrich Klotz; Ingolf Meineke; Thomas Seufferlein; Jürgen Brockmöller
Journal:  Eur J Clin Pharmacol       Date:  2008-10-17       Impact factor: 2.953

Review 8.  Therapeutic drug monitoring of imatinib, nilotinib, and dasatinib for patients with chronic myeloid leukemia.

Authors:  Masatomo Miura
Journal:  Biol Pharm Bull       Date:  2015       Impact factor: 2.233

9.  Pharmacokinetic drug interaction profile of omeprazole with adverse consequences and clinical risk management.

Authors:  Wei Li; Su Zeng; Lu-Shan Yu; Quan Zhou
Journal:  Ther Clin Risk Manag       Date:  2013-05-27       Impact factor: 2.423

10.  Pharmacokinetics and pharmacodynamics of the proton pump inhibitors.

Authors:  Jai Moo Shin; Nayoung Kim
Journal:  J Neurogastroenterol Motil       Date:  2013-01-08       Impact factor: 4.924
  10 in total
  4 in total

1.  Effect of esomeprazole on the oral absorption of dasatinib in a patient with Philadelphia-positive acute lymphoblastic leukemia.

Authors:  Elise Pape; Delphine Michel; Julien Scala-Bertola; Thomas Schiestel; Alexandre Harlé; Stéphane Bouchet; Audrey Contet; Cécile Pochon; Nicolas Gambier
Journal:  Br J Clin Pharmacol       Date:  2016-03-04       Impact factor: 4.335

Review 2.  Applications, Challenges, and Outlook for PBPK Modeling and Simulation: A Regulatory, Industrial and Academic Perspective.

Authors:  Wen Lin; Yuan Chen; Jashvant D Unadkat; Xinyuan Zhang; Di Wu; Tycho Heimbach
Journal:  Pharm Res       Date:  2022-05-13       Impact factor: 4.580

Review 3.  Therapeutic Drug Monitoring and Individualized Medicine of Dasatinib: Focus on Clinical Pharmacokinetics and Pharmacodynamics.

Authors:  Shiyu He; Jialu Bian; Qianhang Shao; Ying Zhang; Xu Hao; Xingxian Luo; Yufei Feng; Lin Huang
Journal:  Front Pharmacol       Date:  2021-12-06       Impact factor: 5.810

4.  A drug-drug interaction study to assess the potential effect of acid-reducing agent, lansoprazole, on quizartinib pharmacokinetics.

Authors:  Jianke Li; Denise Trone; Jeanne Mendell; Patrick O'Donnell; Natalie Cook
Journal:  Cancer Chemother Pharmacol       Date:  2019-08-05       Impact factor: 3.333
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.